Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore
Clarity Pharmaceuticals doses participants with its lead candidate 64Cu-SAR-bisPSMA and completed final assessment in Phase 2 trial of another...
534 Views
Telix Pharmaceuticals (TLX AU): Illuccix Continues to Drive Growth in 1H24; More Products to Come
Telix Pharmaceuticals is acquiring Florida-based RLS Radiopharmacies for $250M. With the acquisition, Telix gets access to RLS’s network of 31...
506 Views
Clarity Pharmaceuticals Ltd (CU6 AU): An Attractive Bet on Red Hot Radiopharmaceutical Field
Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a...
357 Views
Telix Pharmaceuticals (TLX AU): Accelerated US Growth in 1Q24; Two More US Launches Likely in 2024
Telix Pharmaceuticals reports 18% QoQ revenue growth in 1Q24, reaffirms 2024 revenue growth guidance of 35-40% YoY increase, and targets to launch...
321 Views
Weekly Stock Bullfinder - Week of 5/15
One of the lasting legacies of the COVID-19 pandemic was the acceleration of secular trends which were already in place prior to the start pandemic...
232 Views